

## Supplementary Material

### Functional Characterization of the Cyclomarin/Cyclomarazine Prenyltransferase CymD Directs the Biosynthesis of Unnatural Cyclic Peptides

Andrew W. Schultz, Chad A. Lewis, Michael R. Luzung, Phil S. Baran, and Bradley S. Moore

#### **Relative yield of known and novel cyclomarin and cyclomarazine analogs**

Supplementary Figures 1 and 2.....	S2
------------------------------------	----

#### ***N*-(1,1-dimethyl-1-allyl)-tryptophan (2) produced synthetically, enzymatically, and via fermentation**

Supplementary Figure 3. $^1\text{H}$ NMR comparison of (2) <sup>a</sup> .....	S3
---	----

#### **Structure determination of cyclomarazine P**

Supplementary Figure 4. $^1\text{H}$ NMR spectrum of (7) .....	S4
Supplementary Figure 5. HSQC spectrum of (7).....	S5
Supplementary Figure 6. HMBC spectrum of (7).....	S6

#### **Structure determination of cyclomarazine M**

Supplementary Figure 7. $^1\text{H}$ NMR spectrum of (6) .....	S7
Supplementary Figure 8. HSQC spectrum of (6).....	S8
Supplementary Figure 9. HMBC spectrum of (6).....	S9

#### **Structure determination of cyclomarin P**

Supplementary Figure 10. $^1\text{H}$ NMR spectrum of (12) .....	S10
Supplementary Figure 11. HSQC spectrum of (12).....	S11
Supplementary Figure 12. HMBC spectrum of (12).....	S12

#### **Structure determination of cyclomarin M**

Supplementary Figure 13. $^1\text{H}$ NMR spectrum of (11) .....	S13
Supplementary Figure 14. HSQC spectrum of (11).....	S14
Supplementary Figure 15. HMBC spectrum of (11).....	S15

#### **Structure determination of *N*-(1,1-dimethyl-1-allyl)-tryptophan and *N*-(1-propargyl)-tryptophan**

Supplementary Figure 16. $^1\text{H}$ NMR spectrum of (2) <sup>a</sup> .....	S16
Supplementary Figure 17. $^{13}\text{C}$ NMR spectrum of (2) .....	S17
Supplementary Figure 18. $^1\text{H}$ NMR spectrum of (15) <sup>d</sup> .....	S18
Supplementary Figure 19. $^{13}\text{C}$ NMR spectrum of (15) <sup>d</sup> .....	S19
Supplementary Figure 20. $^1\text{H}$ NMR spectrum of (4) .....	S20
Supplementary Figure 21. $^{13}\text{C}$ NMR spectrum of (4) .....	S21


<sup>a</sup>all *N*-(1,1-dimethyl-1-allyl)-tryptophan and *N*-(1-propargyl)-tryptophan spectra recorded in D<sub>2</sub>O unless specified

<sup>b</sup>all cyclomarazine P and M spectra recorded in DMSO-*d*<sub>6</sub>


<sup>c</sup>all cyclomarin P and M spectra recorded in CDCl<sub>3</sub>

<sup>d</sup> recorded in CDCl<sub>3</sub>

## Relative yield of known and novel cyclomarin and cyclomarazine analogs




**Supplementary Figure 1.** Analysis of relative yield of cyclomarin analogs in *Salinispora arenicola* CNS-205 wild type and *cymD*- mutant. Trace A: Wild type *S. arenicola* CNS-205. Trace B-F, *S. arenicola cymD* mutant. Traces C-F represent cultures supplemented with 80 mg/L tryptophan analogs. Trace C: *N*-(1,1-dimethyl-1-allyl)-tryptophan, D: tryptophan, E: *N*-(1-methyl)-tryptophan, F: *N*-(1-propargyl)-tryptophan. Chromatograms recorded at 210 nm. Note similar production levels of cyclomarin M (**11**, trace E) and cyclomarin P (**12**, trace F) in comparison to cyclomarin A (**8**) in trace A and C. Desprenylcyclomarin C (**10**, RT=15.2 min) is produced at levels below the detection limit of this analysis in the *cymD* mutant (trace B), and did not increase to a detectable level with the addition of tryptophan (trace D).




**Supplementary Figure 2** Analysis of production levels of cyclomarazine analogs in *Salinispora arenicola* CNS-205 wild type and *cymD*- mutant. Trace A: Wild type *S. arenicola* CNS-205. Trace B-F, *S. arenicola cymD* mutant. Traces C-F represent cultures supplemented with 80 mg/L tryptophan analogs. Trace C: *N*-(1,1-dimethyl-1-allyl)-tryptophan, D: tryptophan, E: *N*-(1-methyl)-tryptophan, F: *N*-(1-propargyl)-tryptophan. Chromatograms represent the ESI-MS extracted ion for the [M+Na]<sup>+</sup> species as labeled. Note similar production levels of cyclomarazine M (**6**, trace E) and cyclomarazine P (**7**, trace F) in comparison to cyclomarazine A (**5**) in trace A and C. Production of desprenylcyclomarazine (expected [M+Na]<sup>+</sup> = 353) in the *cymD* mutant has never been observed utilizing our assay conditions.


Supplementary Figure 3.  $^1\text{H}$ -NMR comparison of *N*-(1,1-dimethyl-1-allyl)-tryptophan (2)




Supplementary Figure 4.  $^1\text{H}$ -NMR of Cyclomarazine P (7)




Supplementary Figure 5. HSQC NMR of Cyclomarazine P (7)




Supplementary Figure 6. HMBC NMR of Cyclomarazine P (7)




Supplementary Figure 7.  $^1\text{H}$ -NMR of Cyclomarazine M (6)




Supplementary Figure 8. HSQC NMR of Cyclomarazine M (6)




Supplementary Figure 9. HMBC NMR of Cyclomarazine M (6)




*Supplementary Figure 10.*  $^1\text{H}$ -NMR of Cyclomarin P (12)




Supplementary Figure 11. HSQC NMR of Cyclomarin P (12)




Supplementary Figure 12. HMBC NMR of Cyclomarin P (12)




**Supplementary Figure 13.  $^1\text{H}$ -NMR of Cyclomarin M (11)**




Supplementary Figure 14. HSQC NMR of Cyclomarin M (11)




Supplementary Figure 15. HMBC NMR of Cyclomarin M (11)




*Supplementary Figure 16.*  $^1\text{H}$  NMR spectrum of (2)




Supplementary Figure 17.  $^{13}\text{C}$  NMR spectrum of (2)




Supplementary Figure 18.  $^1\text{H}$  NMR spectrum of (15)



Supplementary Figure 19.  $^{13}\text{C}$  NMR spectrum of (**15**)



Supplementary Figure 20.  $^1\text{H}$  NMR spectrum of (4)



Supplementary Figure 21.  $^{13}\text{C}$  NMR spectrum of (4)

